Clinical trial of icotinib combined with thoracoscope minimally invasive in the treatment of non-small cell lung cancer
10.13699/j.cnki.1001-6821.2017.13.004
- VernacularTitle:埃克替尼片联合胸腔镜微创治疗非小细胞肺癌的临床研究
- Author:
Zhong-Hai XIE
1
;
Qi-Bin SHEN
;
Hong-Wei LI
;
Cai-Hua YU
Author Information
1. 湖州市中心医院心胸外科
- Keywords:
non-small cell lung cancer;
icotinib;
thoracoscopic surgery;
midkine;
vascular endothelial growth factor-C;
quality of life
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(13):1181-1183,1187
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and prognosis of serum medium factor (MK),vascular endothelial growth factor-C (VEGF-C) for icotinib combined thoracoscope minimally invasive treatment of non-small cell lung cancer(NSCLC).Methods A total of 94 patients with NSCLC were randomly divided into control group (n =47) and treatment group (n =47).Control group was treated by thoracoscope minimally invasive treatment.Treatment group was orally given icotinib 125 mg,3 times a day,30 d a cycle,and treated for 2 cycles.The recent clinical effect and adverse drug reactions were observed in two groups.To evaluate the quality of life with the scale named quality of life instruments for cancer patients:lung cancer (QLICP-LU).Enzyme linked immunosorbent assay (ELISA) method was used to determinate the serum MK and VEGF-C.Results The disease control rates in treatment group and control group were 76.60％ (36/47 cases),48.94％ (23/47 cases),with significant difference(P ＜ 0.05).After treatment,the physical function,psychological function,social function,common symptoms and side effects,specific module and total quality of life scores were 32.32 ± 6.24,37.87 ± 6.14,29.44 ±5.29,34.02 ±6.32,35.20 ±6.29,168.85 ±30.28 in treatment group,had significant difference with those in control group,which were 24.11 ± 4.17,32.05 ± 4.68,21.26 ± 3.97,28.47 ± 4.81,31.83 ± 5.61,137.72 ±23.24 (P＜0.05).The levels of MK and VEGF-C were (0.42 ±0.13),(0.11 ±0.06) ng · mL-1 in treatment group,had significant difference with those in control group,which were (0.64 ±0.16),(0.16 ±0.08) ng · mL-1 (P ＜ 0.05).The main adverse drug reactions in two groups were diarrhea,nausea and rashes,the incidence rates of adverse reactions in treatment group and control group were 12.77％ (6/47 cases),10.64％ (5/47 cases),with no significant difference (P ＞ 0.05).Conclusion The therapy of icotinib combined thoracoscope for minimally invasive treatment of NSCLC can improve the clinical effect,improve the quality of life,and reduce MK and VEGF-C levels.
